| abstract |
FIELD: pharmaceutics. n SUBSTANCE: group of inventions refers to pharmaceutics and molecular biology and concerns recombinant chimeric protein binding VPAC2 selective receptor, having amino acid sequence SEQ ID NO:13 and having N-terminal methionine and elastin-like polypeptide on c-end, which contains at least 60 repeats VPGXG, as well as pharmaceutical composition containing them. n EFFECT: group of inventions provides longer half-life of blood circulation system, efficiency of binding with receptors or biological activity and/or changed profile of binding with receptor. n 10 cl, 8 ex, 15 dwg |